's Information

Seung-Jung Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. Bifurcation PCI: Evolving Concept and Techniques in AMC Practice After ISCHEMIA Study
  2. Lessons From PREVENT Trial and Subgroup Analysis
  3. Left Main and Multi-Vessel Disease Revascularization: Updated Guideline and Beyond
  4. 15 Years' AMC TAVR
  5. Left Main and Multi-vessel Diseases: Updated Concept and Treatment
  6. Bifurcation PCI: Basic Concept Changes After ISCHEMIA
  7. 15 Years' Journey of AMC TAVR
  8. The PREVENT Trial: Confirmative RCT of Preventive PCI of Vulnerable Plaque
  9. Case 1. Practical Issue of Left Main & Multi-Vessel PCI: Make it Simple!
  10. Revascularization for Left Main Disease: Updated Data, Global Guidelines and Beyond
  11. LM PCI: Make-It-Simple!
  12. What Really Matters in LM Bifurcation PCI: Concept or Technique?
  13. 10 Year's Journey of AMC TAVR
  14. PREVENT Trial
  15. Functionally Insignificant Vulnerable Plaque; Treat or Not?
  16. Non-LM Bifurcation PCI in 2023: Don't Touch Small Side Branch, Evolving Changes in AMC Practice
  17. Insight from All Data for Triple Vessel Disease
  18. Don't Touch Small Side Branch! Concept Changes After ISCHEMIA Study
  19. My Approach to Multi-vessel Disease - Master's Skill Secret
  20. Non-LM Bifurcation Revascularization 2022: Guidelines and Concept Change
  21. The Last 10 Year TAVR Path and Achievement of ASAN MEDICAL CENTER
  22. Updated Techniques and Concepts 2021 for Complex Left Main PCI
  23. Why Mismatching? FFR vs. Angiographic %DS
  24. Minimalist TAVR: AMC Experience
  25. What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
  26. PREVENT: Physiology and Imaging for PREVENTing Future Events
  27. [Debate: Should All CTOs Be Opened?] Cons
  28. MAIN COMPARE: 10-Year Follow-up
  29. What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
  30. Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
  31. 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
  32. LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
  33. PCI vs CABG for Left Main and Multivessel Disease
  34. Integrated Use of FFR and IVUS in LM PCI
  35. TAVR in Asia, Korea, and AMC
  36. PREVENT Trial: Update and Interesting Cases
  37. The Lesson from DECISION-CTO Trial
  38. All the Data from IRIS-FFR Registry
  39. To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
  40. [Debate: Should All CTOs Be Opened?] Con
  41. Top 10 Tips on Left Main PCI
  42. Keynote Lecture on Left Main PCI: Expert's Concept and Technique
  43. Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
  44. Can BRS Stabilize Vulnerable Plaque?: PREVENT
  45. [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
  46. How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
  47. Impact of Complete Revascularization for Multivessel PCI
  48. PREVENT Trial: Update and Insight from Plaque Imaging
  49. Impact of Complete Revascularization for MVD PCI
  50. Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
  51. Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
  52. From STABLE to PREVENT
  53. FFR and Clinical Outcomes: Evidence Has Never Been Stronger
  54. Left Main PCI: The Simpler, The Better
  55. Case 1: Left Main Disease
  56. Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
  57. Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
  58. Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
  59. FFR: How to Change Our Practice?
  60. Integrated Approach for LM PCI Using IVUS and FFR
  61. What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
  62. Please Keep It: IVUS-Guidance for LM Stenting
  63. Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
  64. Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
  65. Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
  66. How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
  67. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
  68. Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
  69. Impact of FFR
  70. IVUS Is Enough!
  71. How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
  72. Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
  73. Asian Multicenter Registry
  74. FFR Guided Clinical Practice of Left Main PCI
  75. [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
  76. Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
  77. Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
  78. 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
  79. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don't. We Can't Predict Fate of Vulnerable Plaque.
  80. Meta-analysis of LM PCI: PCI Using DES vs. CABG
  81. How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
  82. IVUS-MLA and FFR
  83. Coronary Angiography versus FFR: Why Mismatches
  84. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
  85. TAVI in Korea: How to Avoid Conduction Disturbance..
  86. PCI vs CABG from BARI to SYNTAX: Is the Game over?
  87. Functional Evaluation Is Necessary !
  88. Impact of Functional Angioplasty in Our Real Practice!
  89. Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
  90. Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
  91. Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
  92. When and How We Utilize Imaging and Functional Information in LM Stenting
  93. Clinical Outcomes from RCTs and Registries
  94. Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
  95. New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
  96. Why Visual-functional Mismatches?
  97. FFR Guided and IVUS Supported Functional Angioplasty
  98. Device Positioning Is Crucial.
  99. Functional PCI for LM Stenosis: IVUS and FFR Guided
  100. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
  101. Functional Angioplasty - Insight from FFR and IVUS
  102. Why Visual-Functional Mismatches?
  103. Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
  104. Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
  105. It's Not Enough !
  106. Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
  107. Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
  108. Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
  109. Left Main PCI: Where We Are? Where We Are Going?
  110. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
  111. Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
  112. Case Based Learning
  113. Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
  114. PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
  115. Xience V in Real Life
  116. Duration of Dual Antiplatelet Therapy in DES
  117. Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
  118. Coronary Intervention
  119. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  120. DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
  121. Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
  122. Future Clinical Study for Nobori Stent in Korea
  123. The Impact of Diabetes in the DES Long-Term Outcome
  124. Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
  125. Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
  126. Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
  127. Tailores Approach with DES for Long Coronary Lesions
  128. "ZEST" Trial
  129. PCI vs CABG in Left Main Disease: Main Registry Update
  130. Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
  131. Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
  132. How Can We Optimize Good Result in the Long Coronary Lesion ?
  133. Left Main Trifurcation Intervention
  134. LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
  135. VH-IVUS: Matched and Mismatched
  136. Nobori Stent, Update
  137. VH Experience in Real World: Asan Medical Center
  138. How to Treat - Unprotected Left Main Disease
  139. LM Bifurcation Intervention Guideline for COMBAT
  140. Safety and Efficacy of Cypher on Complex Lesion
  141. LM stenting -Cypher
  142. Drug Eluting Stent: Real World Experience(AMC Registry Study)
  143. Long Cypher Multicenter Registry Study
  144. Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
  145. Long-DES: Study presented in TCT 2004
  146. Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
  147. Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
  148. Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
  149. Long Cypher?Multicenter Registry Study in Korea
  150. Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
  151. Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
  152. Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
  153. Percutaneous Mitral Valvuloplasty: State of Art
  154. Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
  155. Why Polymer Coated Paclitaxel Stents
  156. Percutaneous Intervention of Unprotected left main Disease
  157. Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
  158. PCI for Chroic Total Occlusion
  159. Drug-Eluting Stent
  160. Left Main Ostial Stenosis after Aortic Valve Replacement
  161. Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease
Conference Slides
Category